A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes

NCT02146651 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus Type 1

Interventions

DRUG: BioChaperone insulin lispro 0.2U/Kg
DRUG: BioChaperone insulin lispro 0.1U/Kg
DRUG: BioChaperone insulin lispro 0.4U/Kg
DRUG: Humalog®

Sponsor

Adocia